ALNY: Summary for Alnylam Pharmaceuticals, Inc. - Yahoo! Canada Finance

Alnylam Pharmaceuticals, Inc. (NasdaqNM:ALNY) Delayed quote data

After Hours: 16.91

0.02 (0.12%) as of 5:00pm EST on 02/09/10

Last Trade:	16.93 USD
Trade Time:	Feb 9
Change:	0.02 (0.12%)
Prev Close:	16.91
Open:	17.07
Bid:	16.48 x 100
Ask:	17.85 x 100
1y Target Est:	26.17

Day's Range:	16.88 - 17.36
52wk Range:	14.82 - 24.75
Volume:	140,306
Avg Vol (3m):	246,703
Market Cap:	707.93M
P/E (ttm):	N/A
EPS (ttm):	-1.19
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add ALNY to Portfolio

Download Data

HEADLINES

•	Alnylam Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Broadly Covering RNAi Therapeutics
	Business Wire (Mon, Feb 8)

•	Alnylam to Webcast Presentation at The 12th Annual BIO CEO & Investor Conference
	Business Wire (Mon, Feb 1)

•	Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21
	Business Wire (Mon, Jan 25)

•	The Noble Gesture That Wasn't
	at Motley Fool (Thu, Jan 21)

•	BIO Ventures for Global Health Chosen as Administrator of Intellectual Property Pool Involving GSK and Alnylam as Participants
	Business Wire (Wed, Jan 20)

•	Alnylam and Collaborators Present Data from Multiple Pre-Clinical and Clinical Programs at RNAi Keystone Symposium
	Business Wire (Tue, Jan 19)

•	Alnylam and Collaborators Discover Additional Class of Novel Lipid Nanoparticles with Markedly Improved In Vivo Potency for RNAi Therapeutics
	Business Wire (Tue, Jan 19)

•	Alnylams Kreutzer-Limmer I Patent Upheld in German Opposition Proceedings
	Business Wire (Fri, Jan 15)

•	Regulus Therapeutics Present New Pre-clinical Data from Multiple Therapeutic Programs at Keystone Symposium
	Business Wire (Fri, Jan 15)

•	Alnylam Pharma Guides
	Zacks.com (Thu, Jan 14)

•	Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development
	Business Wire (Mon, Jan 11)

More Headlines for ALNY...

ANALYST

EPS Est (next year) (Dec-09) :	-1.26
EPS Est (in 2 years) (Dec-10) :	-1.44
Avg Rec (current)*:	2.4
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutics based on RNA interference (RNAi).

Full Company Profile

Add to Portfolio

Email to a Friend

•

	Sign In [New User? Sign Up]	Finance Home \|Help

Alnylam Pharmaceuticals, Inc. (ALNY)